Genelux Corporation | Redefining Immuno-Oncology

Our Mission: REDEFINE, RESET, CHOICE™

REDEFINE

Redefining immuno-oncology by developing compounds that can overcome some of the most significant challenges associated with cancer.

RESET

Re-sensitize resistant tumors to chemotherapy, re-setting the life clock of late-stage ovarian cancer patients.

CHOICE™

Proprietary discovery platform is the foundation of its oncolytic (anti-tumor) immunotherapy product development program.

OLVI-VEC

Lead clinical candidate in Phase 3 for platinum-resistant/refractory ovarian cancer, demonstrating antitumor activity as monotherapy and in combination.

Why Oncolytic Immunotherapy?

Oncolytic immunotherapy is an immunotherapy modality where viruses selectively replicate and kill tumor cells while leaving normal cells intact.

Viral cell killing has the potential to expose all the tumor’s neoantigens to the immune system and to establish long-term antitumor immunity to improve outcomes for cancer patients.

• Selective replication in tumor cells
• Induction of immunogenic cell death
• Activation of systemic anti-tumor immunity
• Potential for durable responses

Our Scientific Approach

We utilize vaccinia virus (VACV) as the backbone of our therapeutics and diagnostics platform. VACV has a number of characteristics which we consider desirable in an oncolytic virus for clinical applications.

No Genomic Integration

Reduces risk of insertional mutagenesis and enhances safety profile.

Highly Modular

Allows for rapid engineering of transgenes and immune modulators.

Broad Spectrum Activity

Effective across multiple solid tumor types.

Robust Lytic Capabilities

High replication and proliferation in tumor cells.

Powerful Immune Activator

Triggers strong Th1-type immune response.

Systemic Delivery

Intravenous administration enables broad tumor targeting.

The CHOICE™ Discovery Platform

The CHOICE™ discovery platform is the proprietary foundation of our oncolytic immunotherapy product development program. It allows us to rapidly generate new product candidates from conception through the initiation of clinical trials.

✓ Over 500 different versions of vaccinia virus generated
✓ Armed with more than 110 transgenes
✓ Engineered for immune modulation and enhanced tumor killing
✓ Accelerated path from concept to clinical trial

Product Candidates

Olvi-Vec

Lead clinical candidate; modified oncolytic vaccinia virus.

• Phase 3 OnPrime trial in ovarian cancer
• IV administration
• Monotherapy & combination activity

VACV Platform

Proprietary vaccinia virus backbone for multiple candidates.

• Broad tumor tropism
• High replication capacity
• Modular for transgene insertion

CHOICE™ Engineered Vectors

Over 500 variants with immune-modulating transgenes.

• Armed with cytokines & checkpoint modulators
• Designed for enhanced immune activation
• Rapid preclinical-to-clinical translation

OnPrime Phase 3 Program

Registrational trial for platinum-resistant ovarian cancer.

• Actively recruiting
• Primary endpoint: OS & PFS
• Global multicenter study

Recurrent NSCLC Program

Phase 2 trial in non-small cell lung cancer.

• Preparing for initiation
• Combination with checkpoint inhibitors
• Focus on immune-cold tumors

Broad Solid Tumor Pipeline

Potential utility in multiple difficult-to-treat cancers.

• Pancreatic, colorectal, bladder
• Physician-preferred IV route
• Personalized combination strategies

Immuno-Oncology Combinations

Designed to synergize with existing therapies.

• Chemotherapy re-sensitization
• Checkpoint inhibitor enhancement
• Overcoming resistance mechanisms

Next-Gen Candidates

Preclinical pipeline leveraging CHOICE™ platform.

• Armed with novel transgenes
• Targeting immune-suppressive microenvironments
• High-throughput screening enabled

The OLVI-VEC Difference

Most Advanced Program

Believed to be the most advanced clinical development program involving non-local delivery of oncolytic virus.

Versatile & Personal

Potential utility in multiple clinical settings with personalized combination approaches.

Physician-Preferred Administration

Intravenous systemic delivery supported by early clinical trials in solid tumors.

For Investors

Genelux is committed to transparency and engagement with our investors and stakeholders.

Investor Relations

Contact: Austin Murtagh

Firm: Precision AQ

Phone: (212) 698-8696

Email: austin.murtagh@precisionaq.com

Corporate Information

Headquarters: Westlake Village, CA 91361

General Inquiries: (805) 267-9889

Email: info@genelux.com

Visit Investor Relations

Contact Us

For more information about Genelux Corporation, our clinical programs, or partnership opportunities, please visit our official website.

Visit Official Website

Patients: Genelux does not recruit patients for clinical trials. Visit clinicaltrials.gov for information.

Expanded Access: Requests considered under limited circumstances. Participation in clinical trials is currently the best option.

China Quality Suppliers fobcompany.info

Notice for Buyers: If you are a buyer, the above information is generated by AI collection and does not constitute any advice. If necessary, please visit the corresponding official website.

For Domain Owners: If you are the domain owner and do not want to be included by fobcompany.info, please contact support@fobcompany.info via your corporate email to cancel. We will cancel your inclusion within 3 business days.

如果您是域名所有者不想被fobcompany.info收录请用企业邮箱联系support@fobcompany.info 取消收录我们将在3个工作日取消您的收录

Service Request: If you are other domain and want to be included, please contact support@fobcompany.info

如果您是其他域名合作也请联系support@fobcompany.info

Redefining Immuno-Oncology with Next-Generation Oncolytic Immunotherapies